Luminex

According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future. 

The company's system revenues were up 28 percent to $19.5 million and consumables revenues dropped 12 percent to $11.8 million.

Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 firms' share prices decreased. 

The firm said it expects its molecular diagnostics revenues to double year over year with orders continuing to outstrip its supply capabilities. 

The firm will develop a new version of an assay that has received FDA EUA and provides results for up to 96 patient samples in less than four hours.

News items for in vitro diagnostics industry for the week of Sept. 14, 2020.

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.